Stealthy Eikon unveils $148M in funding and ex-Merck exec Perlmutter at helm Eikon Therapeutics joins a growing number of startups researching how proteins move in cells as a basis for drug discovery. Roger Perlmutter joins Eikon as its CEO just four months after he retired as Merck’s top research executive. Shares0
Eikon Therapeutics, a new biotech startup that uses advanced techniques for visualizing proteins and combines that capability with computational approaches to drug screening , has emerged from stealth with $148 million in funding and a veteran Merck executive at the helm. The Series A round of funding that Eikon announced Wednesday was led by The Column Group. Roger Perlmutter, the former president of Merck Research Laboratories is the Hayward, California-based startup’s CEO.